Iovance Biotherapeutics (IOVA) and Nektar Therapeutics presented notable clinical updates on their respective melanoma programs at the Society for Immunotherapy of Cancer annual meeting, which just wrapped over the weekend.
First Iovance, which is developing custom-built immune cells called tumor infiltrating lymphocytes, or TILs. These cells are different from the more well-known and personalized T cell therapies called CAR-Ts that are approved to treat certain types of blood cancers.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
